Showing results (111-120 of 233) with videos related to

Sort By:
Pageof 24
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
British Journal of Haematology|November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytesSyed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
European Journal of Haematology|April 24, 2024
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE studyHans C Lee, Karthik Ramasamy, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple MyelomaCarolina Schinke, Pingping Qu, Syed J Mehdi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania, Sacha Gnjatic, Guido Tricot, et al.
Blood|April 25, 2009
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair, John D Shaughnessy, Yiming Zhou, et al.
Plos One|September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myelomaBo Hu, Yu Chen, Saad Z Usmani, et al.
Bone|February 8, 2021
Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experienceMeera Mohan, Manoj Kumar, Rohan Samant, et al.
Experimental Hematology|January 25, 2003
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee, Ashraf Badros, Bart Barlogie, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Pageof 24